310results about How to "Improve glucose tolerance" patented technology

The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

The invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower the blood sugar level and the blood pressure in mammalian organisms.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.

The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and / or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and / or CB2 receptor. Preferably both the inverse agonist of the CB1 and / or CB2 receptor and the neutral antagonist of the CB1 and / or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).

The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

It is intended to provide compositions and foods for use in the treatment, prophylaxis, or amelioration of diseases or symptoms which can be treated, prevented or ameliorated by activating PPAR, in particular, insulin resistant diabetes and hyperlipidemia. Namely, medicinal compositions usable in treating, preventing or improving diseases or symptoms which can be treated, prevented or ameliorated by activation PPAR which contain humulones, isohumulones or lupulones or pharmaceutically acceptable salts or solvates thereof.

The present invention relates to a lipid system, and methods for using such a lipid system, containing specific relative ratios of omega-3, omega-6, and omega-9 fatty acids. The lipid system may be used independently or as a component of a nutritional product. A lipid system according to the present invention may contain omega-3 fatty acids, omega-6 fatty acids, and omega-9 fatty acids with the ratio of omega-6 fatty acids to omega-3 fatty acids preferably being between 0.25:1 and 3:1, and the ratio of omega-9 fatty acids to omega-3 fatty acids preferably being between 0.4:1 and 3:1. The present invention also relates to methods for administering a lipid system or a nutritional product containing the lipid system to an individual.

The present invention provides a compound represented by general formula (I): or pharmaceutically acceptable salts thereof, wherein W is O, S(O)m, CH2 and the like; R1 is halogen, lower alkyl, halo-lower alkyl, CN and the like; R3 is hydrogen and the like; R4 is hydrogen, halogen, alkyl, halo-lower alkyl, substituted alkyl, aryl, aralkyl, alkoxy, substituted alkoxy, alkanoyl, aroyl, —CONR7(R8), —S(O)mR9, —SO2NR7(R8) and the like; R5 is hydrogen, halogen, alkyl, substituted alkyl and the like; A is —N(R6)CO-A1-COR10 and the like; pharmaceutical compositions containing them and their uses, which have a high affinity to human thyroid hormone receptors, in particular human thyroid hormone receptor β.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The present invention relates to compounds according to the general formulas (I) and / or (Ia), which bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and / or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and / or adipositas.

The invention discloses a special dietary sea food for diabetics. The dietary sea food is prepared by taking the food-borne marine oligopeptides as the main raw material, added by marine bioactive polysaccharides and supplemented with dried marine algae powder, nutrient amino acid, oligosaccharide, nutrients vitamins and minerals, and mixing the substances. The dietary sea food can be produced into powder or particle-like food, and be edible after being dissolved with warm water. The dietary sea food is easy to dissolve, has the greatest biological absorption and maximum bioavailability for ahuman body, high-quality marine protein, activity factors and nutrients are provided for the organism, and the various vitamins and minerals necessary to the human body are supplemented, so as to be beneficial to improving the nutritional status of diabetes. By the interaction of many factors such as food-borne marine oligopeptides, bioactive components in marine bioactive polysaccharides, seaweed powder, amino acid nutrition, the dietary sea food can assist in lowering blood, controlling the blood glucose levels of diabetes, improving immunity and preventing the diabetes complications.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention is a method and composition for the prevention and treatment of type I and type II diabetes in a subject. The composition comprises an IgG-Fc fusion protein where the fusion protein comprises GLP-1, mutant GLP-1, or exendin-4.

This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists / partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and / or FGF21, and variants or fusions of FGF19 and / or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention discloses a health care product with the function of reducing blood sugar. The health care product comprises L-arabinose, chromium-enriched yeast and any one or more of taurine, Chinese wolfberry extract, L-carnitine tartrate and bitter melon extract. The health care product has the functions of reducing the blood sugar and controlling blood fat simultaneously, has good taste, and is particularly suitable for patients with diabetes.

An edible-fiber food for decreasing blood fat and cholesterol, regulating blood sugar, moistening intestine, and preventing constipation, cardiovascular and cerebrovascular diseases, diabetes, intestinal cancer and breast cancer is prepared from water-insoluble fibers (19-80 Wt%) and water-soluble fibers (20-79%).

The invention relates to a solid beverage suitable for patients with diabetes mellitus, which is prepared in the following steps: mixing dry medicine power extracted from semen cassiae, gingkgo, fingered citron, barbary wolfberry fruit, green tea and raw hawthorn and the pulverized mixing powder of rhizoma polygonati, Chinese yam, tuckahoe, kudzuvine root and semen coicis; and then screening to form power for producing and preparing the solid beverage of the patients with diabetes mellitus. The special meal solid beverage has the obvious effects of systemically adjusting glucose metabolism, improving carbohydrate tolerance, insulin sensitivity, insulin function and microcirculation, lightening an insulin load, reducing blood fat and blood viscosity and eliminating radicals and adiposis hepatica. The special meal solid beverage is suitable for patients with diabetes mellitus, obesity, adiposis hepatica, hyperlipemia and hypertension and middle-aged and old people to have.

The invention discloses a traditional Chinese medicine composition with hypoglycemic function and preparation method thereof. The traditional Chinese medicine is made from balsam pear, mulberry leaf and polyghace seche according to a certain weight proportion; and it can be made into any common oral taken preparation form. The Chinese traditional medicine composition in the invention achieves hypoglycemic function, and can be used to treat diabetes.

The invention discloses medicinal steamed bread for treating diabetes. Every 100 grams of steamed bread contain 3-10 percent by weight of medicament which is prepared from the following raw materials in parts by weight: 10-6 parts of Chinese yam, 10-5 parts of gorgon euryale seed, 10-3 parts of fragrant solomonseal rhizome, 8-3 parts of common anemarrhena, 8-3 parts of Mongolian snakegourd root, 8-3 parts of sophora flower, 8-2 parts of sealwort, 8-2 parts of corn stigma, 6-2 parts of dwarf lilyturf root, 6-2 parts of asparagus, 6-2 parts of propolis, 6-1 parts of curcumin and 6-1 parts of mulberry leaf. The medicinal steamed bread can be used for relieving, improving, preventing and treating diabetes type I and diabetes type II, so that the aims of relieving, improving, preventing and treating with medicinal foods are achieved.

The present invention relates to compounds of formula (I), which inhibit dipeptidyl peptidase IV (DPP-IV) and are useful for the prevention or treatment of diabetes, especially type II diabetes, as well as hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis, and various immunomodulatory diseases.